How would you manage a patient with JAK2-positive PV who is not responding to hydroxyurea or IFN-alpha for cytoreduction?   

This is in the setting of a patient who is now on ruxolitinib with rising leukocytosis and thrombocytosis, but cannot be on aspirin due to recent bleed.



Answer from: at Academic Institution
Comments
Medical Oncologist at Taussig Cancer Institute
Would also consider a clinical trial if available!
Sign in or Register to read more

Answer from: at Academic Institution

Answer from: at Academic Institution